PEKING und BRIDGEWATER, New Jersey, 24. Juni 2024 /PRNewswire/ — Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) stellte die Ergebnisse der klinischen Phase-1b/2a-Studie des unabhängig entwickelten, Glucagon-ähnlichen Peptide-1-(GLP-1-)Rezeptoragonisten GZR18…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.